CycloLab picks up the gauntlet to fight coronavirus
The novel coronavirus SARS-CoV-2 is affecting 65 countries and territories around the world with almost 90,000 reported cases and almost
Tag: Dexolve
Gilead Sciences Initiates Two Phase 3 Studies of Investigational SBECD-enabled Antiviral Remdesivir for the Treatment of COVID-19
Gilead Sciences, Inc. yesterday announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of
Gilead uses SBECD-enabled remdesivir (GS-5734) for treating the first case of the 2019 novel coronavirus in the United States
Gilead Sciences’ SBECD-enabled remdesivir (GS-5734) was highlighted in the New England Journal of Medicine last week for treating the first
Marinus Data from SBECD-enabled Ganaxolone Phase 2 Trial in Refractory Status Epilepticus
Marinus Pharmaceuticals, Inc. a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric
Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand Pharmaceuticals Incorporated presented positive results from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN
Positive Results With SBECD-enabled Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders,
Amgen’s Kyprolis, J&J’s Darzalex team up on myeloma survival win
After years of slow growth, Amgen’s Kyprolis finally looks poised to break the blockbuster barrier in 2019, and new data
Clinical trial on Noninfectious Anterior Uveitis – SBECD offering disease resolution
Aldeyra Therapeutics Announced Results from the SOLACE Trial in Noninfectious Anterior Uveitis. The main points are: Statistical Significance Not Achieved
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today
Sage Therapeutics Announces FDA Approval of ZULRESSO™ (SBECD-enabled brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression
Approval based on results from three pivotal trials showing treatment with ZULRESSO provided significant and rapid reduction of depressive symptoms